Elicera Therapeutics AB
Research Elicera Therapeutics AB (ELIC) on Bullrun: market cap SEK 190.20M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerELIC
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencySEK
- Market capSEK 190.20M
- Financial periodQ1 2026
- RevenueSEK 0
- Net income-SEK 5.06M
- Free cash flow-SEK 6.98M
Valuation Snapshot
latest market cap is SEK 190.20M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 0 | -SEK 17.41M | -SEK 21.55M | n/a | -0.41 | SEK 24.85M | n/a | SEK 23.36M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-29 | SEK 190.20M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 SEK.
About Elicera Therapeutics AB
Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Elicera Therapeutics AB's market cap?
Elicera Therapeutics AB's market capitalization is SEK 190.20M.
What does Elicera Therapeutics AB do?
Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer.